A rationale for the unlike potency of avibactam and ETX2514 against OXA-24 β-lactamase

Diazabicyclooctanone inhibitors such as ETX2514 and avibactam have shown enhanced inhibitory performance to fight the antibiotic resistance developed by pathogens. However, avibactam is ineffective against Acinetobacter baumannii infections, unlike ETX2514. The molecular basis for this difference has not been tackled from a mo-lecular approach, precluding the knowledge of relevant information. In this article, the mechanisms involved in the inhibition of OXA-24 by ETX2514 and avibactam are studied theoretically by hybrid QM/MM calculations. The results show that both inhibitors share the same inhibition mechanisms, comprising acylation a deacylation stages. The involved mechanisms include the same number of steps, transition states and intermediates; although they differ in the involved activation barriers. This difference accounts for the dissimilar inhibitory ability of both inhibitors. The molecular reason for this is the endocyclic double bond in the piperidine ring of ETX2514 increasing the ring strain and chemical reactivity on the N6 and C7 atoms, besides the methyl substituent, which enhance the hydrophobic character of the ring. Furthermore, Lys218 and the carboxylated Lys84 of ETX2514, play a crucial role in the mechanism by coordinating their protonation states in an on/off (protonated/depro-tonated) manner, favoring the proton transference between the residues and the inhibitor.

Automated summary

This article theoretically studied the inhibitory mechanisms of ETX2514 and avibactam against OXA-24. The results showed that both inhibitors share similar steps and intermediates in the inhibition process, but have different activation barriers. The endocyclic double bond and methyl substituent in the piperidine ring of ETX2514 contribute to its stronger inhibitory ability. Additionally, Lys218 and carboxylated Lys84 of ETX2514 play a crucial role in the mechanism by coordinating their protonation states.